Jun 08, 2023 / 05:00PM GMT
Andrew Tsai - Jefferies & Company, Inc. - Analyst
With us today and it's my pleasure to have the Avadel team with me. I've got to the right of me Greg Divis, CEO; and to the right of him Richard Kim, CCO. Welcome both of you. Great. And so team, maybe briefly for a couple minutes for those in the audience who might not be as familiar with the Avadel story can you give us a background about your company. Congratulations, by the way, on the approval, but I'll let you take it away from there.
Greg Divis - Avadel Pharmaceuticals plc - CEO
Yeah I won't belabor almost 40 years of history of the company. I think most importantly over the last number of years we've been exclusively focused on a rare sleep medicine in particular narcolepsy with our lead program LUMRYZ, which as of May 1, was approved by the FDA for patients with narcolepsy suffering from excessive daytime sleepiness and or cataplexy.
Along with that FDA approval was LUMRYZ was granted full orphan drug exclusivity and was determined to be clinically superior to the first-generation twice
Avadel Pharmaceuticals PLC at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers